Keiretsu Forum Regions Demonstrate Investment Stability Amidst Industry-Wide Downturns
23 avr. 2024 07h29 HE
|
Keiretsu Forum Mid-Atlantic
In 2023, Keiretsu Forum MA-SE-TX region’s curated investment portfolio maintained a confident stance within an otherwise retreating investment ecosystem.
Biotech Seeds Global Strategic Business Report 2024: A US$119.2 Billion Market by 2030, growing at a CAGR of 7.3% During 2023-2030
23 avr. 2024 03h17 HE
|
Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Biotech Seeds - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Biotech Seeds estimated...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
19 avr. 2024 07h13 HE
|
Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer
19 avr. 2024 04h08 HE
|
Amarna Therapeutics
Leiden, The Netherlands, 19 April 2024 – Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Type...
Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024
18 avr. 2024 16h30 HE
|
Rapid Micro Biosystems, Inc.
LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation...
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
18 avr. 2024 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
18 avr. 2024 07h30 HE
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and
Investigator-Initiated Pre-Clinical Studies at ESCMID Global (Formerly ECCMID)
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
18 avr. 2024 06h00 HE
|
Biosplice Therapeutics, Inc.
Presentation of OA-07 Phase 3 Long-Term Results for Lorecivivint and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
17 avr. 2024 16h05 HE
|
Serina Therapeutics, Inc.
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17 avr. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise